key: cord-0800191-zs1g9uf7
authors: Lü, Jian-Ming; Liang, Zhengdong; Liu, Dongliang; Zhan, Bin; Yao, Qizhi; Chen, Changyi
title: Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids
date: 2021-08-25
journal: Pharmaceuticals (Basel)
DOI: 10.3390/ph14090841
sha: db007f441080df8dcc95a717d85460117e0d1929
doc_id: 800191
cord_uid: zs1g9uf7

We previously reported a new polymer, lactic-co-glycolic acid-polyethylenimine (LGA-PEI), as an improved nanoparticle (NP) delivery for therapeutic nucleic acids (TNAs). Here, we further developed two antibody (Ab)-conjugated LGA-PEI NP technologies for active-targeting delivery of TNAs. LGA-PEI was covalently conjugated with a single-chain variable fragment antibody (scFv) against mesothelin (MSLN), a biomarker for pancreatic cancer (PC), or a special Ab fragment crystallizable region-binding peptide (FcBP), which binds to any full Ab (IgG). TNAs used in the current study included tumor suppressor microRNA mimics (miR-198 and miR-520h) and non-coding RNA X-inactive specific transcript (XIST) fragments; green fluorescence protein gene (GFP plasmid DNA) was also used as an example of plasmid DNA. MSLN scFv-LGA-PEI NPs with TNAs significantly improved their binding and internalization in PC cells with high expression of MSLN in vitro and in vivo. Anti-epidermal growth factor receptor (EGFR) monoclonal Ab (Cetuximab) binding to FcBP-LGA-PEI showed active-targeting delivery of TNAs to EGFR-expressing PC cells.

Cancer was the second leading cause of death, while the heart disease was the first leading cause of death in the United States (US) in 2018 [1] . However, cancer emerged recently as the leading cause of death in many states in the US [2] . It is estimated that the total new cancer cases and cancer deaths in US are 1,898,160 and 608,570, respectively, in 2021. New cases and death from pancreatic cancer (PC) in the US are estimated to be 60,430 and 48,220, respectively, in 2021. Now, PC is the third leading cause of cancer death following lung cancer (131,880 deaths) and colorectum cancer (52,980 deaths) [3] . For all stages combined, the 5-year relative survival rate is the lowest for PC (9%) among all cancer types. Even for patients with resectable disease, the overall survival rate is only 17% [3, 4] . The poor prognosis is mainly due to lack of early diagnosis, tumor pathology, and progression and limited efficacy of available drugs and other therapies [3, 5] . Therefore, there is an urgent need for the development of more effective therapeutic strategies against PC.

Therapeutic nucleic acid (TNA) is one of these new strategies for the treatment of many diseases, including cancer. TNA includes specific genes (DNA and mRNA), antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA (miRNA) analogs, miRNA inhibitors (antagonists), aptamers, ribozymes, CpG, decoy NAs, CRISPR-Cas, and able to increase nuclear-envelope permeability, which may help plasmid DNA entering into the nucleus [22] . Branched PEI (such as 25 kDa) is one of the most commonly used TNA delivery vectors in vitro and in vivo due to its highly effective endosomal escape activity. However, clinical use of branched PEI has been limited because of its potential toxicity caused by the disruption of the cell membrane or damage of the mitochondrial membrane at relatively high doses [23, 24] . The toxicity of PEI has been associated with its molecular weight and structure. Free PEI seems more toxic than the PEI-NA complex [25] .

In order to reduce the potential toxicity of branched PEI for TNA delivery, chemical modifications of PEI have been actively studied. In fact, rational designs of chemical modifications of branched PEI or conjugation of targeting groups or PEGylation are relatively easy because of the presence of many amino groups in PEI [26] . For examples, PEI has been modified by various polymers, hydrophobic chemicals, and other molecules such as dextran, cyclodextrins, chitosan, polyethylene glycol, polyethylene glycol (PEG), acetate, butanoate, hexanoate, folic acid, peptides, proteins, metals, and more. PEI-based delivery systems for TNAs have been broadly investigated in clinical trials for HIV vaccines and many types of cancers, including PC [27] . Recently, we developed a new modified PEI, in which lactic-co-glycolic acid (LGA) single units are covalently linked to the branched PEI (25 KDa) . The new LGA-PEI polymer spontaneously formed NPs with TNAs and showed much lower toxicity than control PEI NPs in mouse models and in cell cultures, while also showing high transfection efficiency for DNA or RNA in vitro and in vivo [28] .

One of the important strategies of PEI modification is to achieve an active-targeting delivery of TNAs, improving therapeutic efficacy while minimizing off-target damage in healthy tissues [29] . Antibodies (Abs) or Ab fragments as targeting ligands are the most commonly used for conjugation on the surface of NPs for active-targeting delivery because they have high affinity to specifically bind to antigens or receptors on cancer cell surfaces [30] . In addition, various types of proteins, small peptides, or other molecules were used to conjugate on the surface of NPs to achieve active targeting to cancer cells, including transferrin, arginine-ycine-aspartic acid (RGD) peptide, cyclic arginine-glycineaspartic acid-tyrosine-lysine c(RGDyK), bombesin peptide, NR7 peptide, hyaluronic acid (HA), folate, aptamers, galactose, and lactose [30] . Modifying the PEIs using targeting ligands specifically bind unique cell surface markers of diseased cells, not expressed on the normal healthy cells. For example, humanized anti-Her-2/neu monoclonal Ab, Trastuzumab, covalently conjugated to branched PEI (25 KDa), more effectively delivered plasmid DNA into Her-2/neu-expressing breast cancer cells [31] . We and others have reported that mesothelin (MSLN) is widely expressed in human cancers; for example, the majority (80-90%) of PC and ovarian cancers and 100% of epithelial mesotheliomas highly express MSLN [32] [33] [34] [35] [36] [37] [38] [39] . It is also overexpressed in lung adenocarcinomas, gastric cancers, triple-negative breast cancers, uterine serous carcinoma, acute myeloid leukemia, and cholangiocarcinoma [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] (Supplementary Table S2 ). However, MSLN has only limited expression in mesothelial cells lining the pleura, pericardium, and peritoneum [39] ; no MSLN expression is found in solid organs such as the heart, kidney, and liver [34] . Thus, MSLN has become a unique biomarker for targeting cancer therapy. In the current study, we successfully covalently linked a single-chain variable fragment antibody against MSLN (MSLN scFv) to our LGA-PEI polymer and showed MSLN-targeted delivery of TNAs in PC cells and animal models. Furthermore, we rationally designed and conjugated our LAG-PEI polymer with a special Ab fragment crystallizable region (Fc)-binding peptide (FcBP) [52] , which is able to bind to IgG (full Abs) for active-targeting delivery. Since the expression of MSLN is closely associated with the high expression of cell surface epidermal growth-factor receptor (EGFR) in PC cells [53] , we used a clinical grade anti-EGFR Ab (Cetuximab, C255) for its binding to FcBP-LGA-PEI NPs, achieving targeting delivery of TNAs in PC cells with high expression of EGFR. EGFR is an important molecular marker and target for many types of cancers including PC, breast cancer, glioblastomas, and colorectal cancer [54] [55] [56] [57] . In the current study, we developed two targeting-delivery systems based on our new LGA-PEI polymer, which may deliver a variety of types of potential TNAs including DNA, miRNA, and modified mRNA, and may have broad clinical applications for effective treatments of PC and other types of cancers that express specific biomarkers.

We tested the delivery of miR-198 mimics, miR-520h mimics, and non-coding RNA X-inactive specific transcript (XIST) fragments, which may have therapeutic potential for cancers. We previously identified a novel network "interactome" of tumorigenic prognostic factors including miR-198, MSLN, NF-kB, homeobox transcription factor POU2F2 (OCT-2), pre-B cell leukemia homeobox factor 1 (PBX-1), and valosincontaining protein (VCP). More importantly, this interactome is interconnected through a tumor suppressor, miR-198, which is able to both directly and indirectly modulate the expression of various factors of this network and plays a critical role in PC pathogenesis [58] . When miR-198 expression is reduced in PC tissues, patient survival is dismal; while miR-198 level is relatively high, patients have a better prognosis and increased survival. In addition, miR-198 replacement reverses tumorigenicity in experimental models. These data indicate that miR-198 has therapeutic potential for PC. miR-198 has been shown to have a potent tumor-suppressor function in other types of cancers including renal cell carcinoma, ovarian cancer, lung cancer, and prostate cancer [59] [60] [61] [62] . Furthermore, many studies have demonstrated that miR-520h could significantly inhibit tumor progression or prevent chemotherapy drug resistance in different types of cancers such as PC, multiple myeloma, and gastric cancer [63] [64] [65] . It has been reported that XIST plays a tumor-suppressor function in many types of cancers including classical Hodgkin's disease, renal cell carcinoma, breast cancer, and prostate cancer [66] [67] [68] [69] . Green fluorescence protein gene (GFP) was also used as an example of plasmid DNA. In the current study, we focused on the production and characterization of our new delivery systems as well as their delivery efficiency of these potential TNAs in vitro and in vivo.

We previously reported that synthesized LGA-PEI polymers still have about 50% primary amine groups of PEI left [28] . In the current study, we established two Ab-guided LGA-PEI NP delivery systems for TNAs. The first is MSLN scFv-LGA-PEI polymer, for which MSLN scFv is covalently linked to LGA-PEI, and the second is FcBP-LGA-PEI polymer, in which FcBP is covalently linked to LGA-PEI; any full Ab (IgG) can bind to the FcBP-LGA-PEI polymer. For the preparation of the MSLN scFv-LGA-PEI polymer ( Figure 1A and Figure S1 ), we used bi-functional PEG (Mal-PEG-NHS) to covalently link the MSLN scFv fragment to LGA-PEI. First, Mal-PEG-NHS reacted with LGA-PEI at a desired molar ratio in 0.1 M phosphate buffer (pH 7.0) at room temperature for 3 h. Primary amine of the PEI attacked the ester bond of Mal-PEG-NHS, thus replacing the NHS group to conjugate Mal-PEG to PEI of the LGA-PEI through amide linkage. The Mal-PEG-PEI-LGA was purified by gel-permeation chromatography. The MSLN scFv fragment was then added to the Mal-PEG-PEI-LGA at a desired molar ratio and reacted at room temperature overnight under nitrogen. The hydrosulfyl group (-SH) (thiol) of cysteine in the peptide could add to the C=C double bond of the maleimide group in Mal-PEG-PEI-LGA, forming a stable S-C bond (click reaction). The yield of MSLN scFv-LGA-PEI and FcBP-LGA-PEI was about 70%, estimated from the starting material and final product weights. Therefore, the MSLN scFv fragment was conjugated with LGA-PEI. We produced a recombinant MSLN scFv (SS1) based on the published gene sequence identified by phage display [70, 71] . We cloned and expressed MSLN scFv as a soluble recombinant protein with a His tag in yeast (Pichia pastoris X33 strain). SDS-PAGE assay indicated that MSLN scFv is a 30 kDa protein with 95% purity ( Figure 1B) . The MSLN scFv-LGA-PEI was purified by dialysis against 0.1 M NaCl. This MSLN scFv-LGA-PEI polymer is ready for loading TNAs and specifically delivering to cancer cells with the expression of MSLN. MSLN scFv-LGA-PEI polymers effectively load different types of NAs including plasmid DNA, microRNA (miRNA) mimics, and modified mRNAs (mmRNAs). For example, NPs were formed from a total of 5 µg of two polymers, MSLN scFv-LGA-PEI and LGA-PEI, at different ratios with 2 µg of plasmid DNA (double-stranded, circular DNA, 4.7 kbp) in 50 µL water. The NP solution was diluted 100 times in water and the particle size was measured by the dynamic light-scattering method (Zetasizer Nano ZS90, Malvern, Worcestershire, UK). The average particle sizes varied slightly with the ratios of the MSLN scFv-LGA-PEI and LGA-PEI polymers, ranging from 112 nm at 100% MSLN scFv-LGA-PEI with DNA to 153 nm at 100% LGA-PEI with DNA ( Figure 1C and Supplementary Table S3 ). Additionally, NPs were formed from pure MSLN scFv-LGA-PEI (5 µg) with 2 µg vector plasmid (doublestranded, circular DNA, 3.2 kbp) and plasmid DNA containing XIST gene fragments (255 nucleotides), XIST255 mmRNA (single stranded RNA, 255 bases), or control mmRNA. Average particle sizes were around 100 nm. NPs formed from pure MSLN scFv-LGA-PEI and DNA showed smaller particles sizes than those formed from MSLN scFv-LGA-PEI mixed with LGA-PEI and DNA or pure LGA-PEI and DNA ( Figure 1D ). Furthermore, NPs were also formed from a total of 1.5 µg of two polymers, MSLN scFv-LGA-PEI and LGA-PEI, at different ratios with 1 µg of miR-198 mimics (double-stranded, 23 bp) in 50 µL water. The average particle sizes varied slightly with the ratios of MSLN scFv-LGA-PEI and LGA-PEI polymers, ranging from 126 nm at 100% MSLN scFv-LGA-PEI with miR-198 mimics to 332 nm at 100% LGA-PEI with miR-198 mimics ( Figure 1E and Supplementary Table S4 ). As an example, scanning electronic microscopy (SEM) and energy-dispersive spectroscopy (EDS) analysis confirmed NP formation from LGA-PEI (1.5 µg)/miR-520h mimics (1 µg), and from MSLN scFv-LGA-PEI (1.5 µg)/miR-520h mimics (1 µg). The SEM images indicated that the particle sizes were about 100-200 nm; the EDS analysis showed these particles containing a large amount of oxygen and phosphorus elements, indicating particles containing NAs ( Figure 1F ).

For preparation of the FcBP-LGA-PEI polymer, we covalently conjugated the FcBP (DCAWHLGELVWCT), previously discovered by bacteriophage display and which shared the same binding site of the Fc region of IgG Abs from bacteria Staphylococcus aureuss protein A and treptococcal protein G [52] , to LGA-PEI through a link molecule (bi-functional PEG, Mal-PEG-NHS). Extra glycine residues are added to both sides of the FcBP to enhance their conformational flexibility and to provide full access for the Ab. Cysteine is located at both ends of the FcBP, CGGGGDCAWHLGELVWCTGGGGC. The cysteine in one end is used to conjugate the peptide to LGA-PEI through bi-functional PEG, Mal-PEG-NHS. We used bi-functional PEG (Mal-PEG-NHS) to connect FcBP to LGA-PEI. Mal-PEG-NHS reacted with LGA-PEI to form Mal-PEG-PEI-LGA. The FcBP was added to the Mal-PEG-PEI-LGA at a desired molar ratio though a click reaction between the thiol of cysteine in the peptide and maleimide group in Mal-PEG-PEI-LGA, forming a stable S-C bond. Therefore, FcBP was conjugated with LGA-PEI (Supplementary Figure S1 ). The FcBP-PEG-PEI-LGA was further purified by dialysis against 0.1 M NaCl. This new FcBP-LGA-PEI polymer was used for loading specific Abs to the NP for active-targeting delivery to specific cell types. The FcBP has an absorbance at 280 nm, while LGA-PEI does not. The standard curve of spectroscopic analysis for the FcBP standard at 280 nm with different concentration was established to detect FcBP content covalently linking to LGA-PEI ( Figure 2A ). Successful FcBP conjugation into LGA-PEI was confirmed by spectrophotometry analysis ( Figure 2B ). The new polymer FcBP-LGA-PEI also had absorbance at 280 nm, which showed a similar peak as that of FcBP, indicating the conjugation of FcBP to the LGA-PEI polymer. For FcBP-LGA-PEI (10 mg/mL), A280 is about 0.32 after corrected from baseline and background subtraction; so [FcBP] = (0.32 + 0.0006)/0.0047 = 68 µg/mL, and thus, 100% × 0.068 (µg/mL)/10 (mg/mL) = 0.68%. By using FcBP as a standard, we estimate that the FcBP-LGA-PEI contains about 0.68% FcBP in weight. The new FcBP-LGA-PEI polymer effectively loaded plasmid DNA and included a full Ab, anti-EGFR Ab, as an example, to form NPs, which were confirmed by dynamic light-scattering analysis ( Figure 2C and Supplementary Table S5 ). Anti-EGFR Ab attached to the FcBP-LGA-PEI/DNA NPs did not increase the particle sizes based on the dynamic light-scattering measurements. Nucleic acid loading efficiency of our polymers (LGA-PEI, MSLN scFv-LGA-PEI and anti-EGFR Ab/FcBP-LGA-PEI) was confirmed by gel retardation assay (Supplementary Figure S2) . 

In our previous study [32] , we established stable transfection of MSLN in PC cell line Mia-CaPa2 (Mia-MSLN cells) as well as vector control cells (Mia-vector cells). In the current study, we confirmed that Mia-MSLN cells have a higher expression of MSLN than Mia-vector cells. Furthermore, EGFR expression in Mia-MSLN cells was much higher than that in Mia-vector cells ( Figure 3A ). MSLN could enhance EGFR expression in PC cells [53] . Both MSLN and EGFR molecules were used as targets for our Ab-guided NP delivery systems. For the MSLN scFv-LGA-PEI system, we loaded the MSLN scFv-LGA-PEI/LGA-PEI polymer or LGA-PEI polymer (control) with fluorescence labelled miR-520h mimics or miR-198 mimics to form NPs, and determined their binding and internalization efficiency to Mia-MSLN cells as compared with Mia-vector cells. Indeed, MSLN scFv-LGA-PEI/miR-520h mimics NPs ( Figure 3B ,C) or MSLN scFv-LGA-PEI/miR-198 mimics NPs ( Figure 4A ,B) showed a significantly higher level of both cell binding and internalization in Mia-MSLN cells than those in Mia-vector cells. To further confirm the gene delivery efficiency, MSLN scFv-LGA-PEI polymer or LGA-PEI polymer as a control was loaded with green fluorescence protein (GFP)-gene-containing plasmid to form NPs and transfected to Mia-MSLN cells for 24 h. GFP expression was much higher with the delivery of MSLN scFv-LGA-PEI/GFP plasmid NPs than that of LGA-PEI/GFP plasmid NPs, indicating the effect of MSLN scFv targeting MSLN on Mia-MSLN cells ( Figure 4C ). 

Recently, we developed many PDX lines from human PC surgical specimens. One of the PDX lines (PAN3) was used in the current study. PDX3 (PAN3) showed high expression of MSLN as compared with the normal human pancreas tissue by immunofluorescence staining ( Figure 7A ). To determine whether MSLN scFv-LGA-PEI NPs with NAs could target MSLN-expressing cancer tumor tissues in vivo, we orthotopically implanted the PDX line (PAN3) into the pancreas of an NSG mouse (NOD scid gamma mouse) for 3 weeks, when the tumor was established. miR-520h labeled with DY-547 was loaded into the MSLN scFv-LGA-PEI or LGA-PEI polymer to form NPs. MSLN scFv-LGA-PEI/miR-520h mimics NPs or LGA-PEI/miR-520h mimics NPs were randomly injected into the mouse through the tail vein (n = 4 for each group). The mice were euthanized 1 day later, and the PAN3 tissues were harvested for immunofluorescence image and H&E staining. The mouse treated with MSLN scFv-LGA-PEI/miR-520h mimics NPs showed stronger red fluorescence in the PAN3 tumor than that treated with the LGA-PEI/miR-520h mimics NPs did, indicating MSLN scFv-LGA-PEI can deliver more RNA into the tumor tissue with high MSLN expression than LGA-PEI does ( Figure 7B ). In addition, a Mia-MSLN cell-line-based xenograft mouse model was also used to determine the targeting delivery of MSLN scFv-LGA-PEI NPs with NAs. Mia-MSLN cells (5 × 10 5 in 50 µL) were orthotopically injected into the pancreas of an NSG mouse for 3 weeks, when the tumor was established. miR-198 mimics labeled with CY3 was loaded into MSLN scFv-LGA-PEI or LGA-PEI polymer to form NPs. MSLN scFv-LGA-PEI/miR-198 mimics NPs or LGA-PEI/miR-198 mimics NPs were randomly injected into the mouse through the tail vein (n = 4 for each group). The mice were euthanized in next day, and mouse Mia-MSLN cell-derived tumors were harvested for fluorescence analysis. The mouse treated with MSLN scFv-LGA-PEI/miR-198 mimics NPs showed an enhanced red fluorescence in the Mia-MSLN tumors compared with the mouse treated with LGA-PEI/miR-198 mimics NPs, suggesting that MSLN scFv-LGA-PEI polymer more efficiently delivers RNA into the pancreatic tumors with high expression of MSLN ( Figure 7C ). LGA-PEI NPs delivering miR-520h mimics into pancreatic cancer tissues in a mouse model. The PDX line (PAN3) was orthotopically implanted into the pancreas of an NSG mouse (NOD scid gamma mouse) for 3 weeks. miR-520h was labeled with DY-547 and loaded into MSLN scFv-LGA-PEI or LGA-PEI polymer to form NPs. MSLN scFv-LGA-PEI (15 µg)/miR-520h mimics (10 µg) NPs or LGA-PEI (15 µg)/miR-520h mimics (10 µg) NPs were randomly injected into the mouse through the tail vein (4 mice/group). The mice were euthanized the next day, and the PAN3 tissues were harvested for immunofluorescence image and H&E staining. Furthermore, we also determined the targeting delivery of anti-EGFR Ab/FcBP-LGA-PEI miR-198 mimics NPs into Mia-MSLN cell-derived xenografts in the mouse model. Mia-MSLN cells were orthotopically injected into the pancreas of a NSG mouse for 3 weeks, when the tumor was established. Anti-EGFR Ab/FcBP-LGA-PEI miR-198 mimics NPs or HIV gp120 Ab/FcBP-LGA-PEI/miR-198 mimics NPs as the control randomly injected the tumor-bearing mouse through tail vein (n = 4 for each group). The mice were euthanized the next day, and the Mia-MSLN tumor tissues were harvested for fluorescence image analysis. The mouse treated with anti-EGFR Ab/FcBP-LGA-PEI/miR-198 mimics NPs showed significantly higher fluorescence intensity in the Mia-MSLN tumors as compared with that in mice treated with HIV gp120 Ab/FcBP-LGA-PEI/miR-198 mimics NPs, indicating that anti-EFGR Ab guides NP delivery of nucleic acids into Mia-MSLN tumors with high expression of EGFR ( Figure 7D ).

In the current study, we extended our previously developed new LGA-PEI polymer as an improved NP platform for delivering TNAs to active-targeting delivery systems by covalent conjugation of MSLN scFv Ab fragment or FcBP for binding any full Ab (IgG). These Ab-guided LGA-PEI delivery systems are capable of effectively loading TNAs including plasmid DNA, mRNA, and miRNAs to form stable and functionalized NAs. MSLN scFv-LGA-PEI NPs with TNAs significantly improve their binding and internalization as well as gene expression in PC cell lines with high expression of MSLN, a cell surface marker, in both cell culture and mouse models. As a model, we used an FDA-approved humanized anti-EGFR monoclonal Ab (Cetuximab, Eli Lilly and Company, Indiana, USA), binding to our new FcBP-LGA-PEI polymer, which effectively loads TNAs, forms functionalized NPs, and specifically targets PC cell lines with high expression of ERGR in vitro and in vivo. These results demonstrate that two Ab-guided NP delivery platform technologies built up from our novel LGA-PEI polymer may have great potential for clinical applications of the active-targeting therapy with TNAs for PC and other types of cancers with unique and specific cell surface markers.

The targeting drug delivery system could significantly improve the efficacy of the medication, while also reducing side effects as compared with the traditional drug delivery systems such as oral ingestion and intravenous administration [29] . In fact, the NP-based drug delivery system is the passive-targeting drug delivery for cancers and some other diseases through the mechanism of the EPR effect [12, 13] . Furthermore, an NP-based drug delivery system can become the active-targeting drug delivery through conjugation of cell-specific ligands or Abs, which allow the NP to bind specifically to the cell that has the complementary receptor or unique cell surface biomarkers. NP-based active targeting can enhance the effects of passive targeting to make the NP more specific to a target site [29] . MSLN, a tumor-associated antigen, is a clinically validated target for immunotherapy and other treatment strategies for PC, mesothelioma, and ovarian cancer, including immunotoxins, vaccines, chimeric monoclonal Abs, Ab-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy [72] . For the first time, we developed NPbased active-targeting delivery of TNAs specifically towards MSLN-expressing PC cells. We produced a MSLN Ab scFv (SS1) based on the published information [70, 71] . In fact, scFv (SS1) was developed by optimization of amino acid sequences from a parental anti-MSLN scFv isolated from a phage display library and showed at least five times the binding affinity for MSLN than the parental Ab scFv [70, 71] . MSLN scFv (SS1) was more effectively internalized into cells after binding to the cell surface MSLN as compared with anti-MSLN monoclonal Ab K1 [70, 71, 73] . MSLN scFv (SS1) was used for the development of a recombinant immunotoxin [74, 75] and CAR-T therapy [76] that targets MSLN-expressing cancer cells in preclinical models and clinical trials. In the current study, we covalently linked MSLN scFv to the LGA-PEI polymer though the Mal-PEG-NHS polymer as a heterobifunctional crosslinker. Primary amine of PEI attacks ester bond between PEG and NHS groups of the Mal-PEG-NHS polymer, thus replacing the NHS group to conjugate Mal-PEG to the primary amine of PEI of the LGA-PEI polymer. The hydrosulfyl group (-SH) (thiol) of cysteine in MSLN scFv is also ready to react the C=C double bond of the maleimide group of the Mal-PEG-PEI-LGA under nitrogen to form a stable S-C bond (click reaction) for linking MSLN scFv to Mal-PEG-PEI-LGA.

It is well known that hydrophilic polymer PEG is often used to modify PEI for reducing the surface charge, while increasing solubility of the PEI-based NPs in vivo. Such a modification strategy is termed "stealth technology"; thereby, PEGylation of PEIs could diminish the interaction of the NPs with blood components, reduce the uptake by macrophages, and increase blood circulation time for the effective delivery [26, 77] . The PEG-PEI copolymer showed good transfection and low cytotoxicity compared with PEI alone [78] . An optimal amount of PEG for PEI modification is important because heavy PEGylation of PEI could reduce the TNA-binding capacity of the polymer [78] . Further functionalization of the PEI polymer is to combine the PEG stealth technology with the use of ligands and Abs (scFv or full Abs) for the active-targeting delivery though a hetero-bifunctional crosslinker such as α-maleimide-ω-N-hydroxysuccinimide ester polyethylene glycol (Mal-PEG-NHS ester) [79, 80] . Thiol-ene click reaction including thiolene radical and thiol Michael addition reaction is one of the most commonly used methods for preparing peptide-polymer conjugates [81] . In the current study, the maleimide of MAL-PEG-NHS can react with a free thiol group of cysteine residue of MSLN scFv by the Michael addition reaction, while the NHS can react with the primary amine of the PEI-LGA polymer. It is believed that the Michael addition reaction is of high efficiency and selectivity, and it could be achieved under mild conditions without interference from other functionalities of the polymer [81] . ScFv consists only of the variable regions of immunoglobulins and has the same targeting specificity of the parental form of full Ab. Because of the small size, scFv has some advantages for the active-targeting delivery system such as more conjugation, low immunogenicity, and more efficient tissue penetration compared with full Abs [82, 83] . Modified branched PEI for the delivery system should remain its positively charged amine groups (primary, secondary, and tertiary), which enable effective electrostatic binding and condensation of negatively charged TNAs. Secondary and tertiary amines of modified PEI are also critical for its buffering capacity and polymer swelling at the acidic pH of the endosomes [84] . Our MSLN scFv-LGA-PEI copolymer effectively loaded double-stranded plasmid DNA, single-stranded RNA and miRNA mimics, and formed NPs with sizes of around 100 nm, which are ready for active-targeting delivery.

In the current study, we also developed a new nanoplatform technology based on our LGA-PEI polymer, which covalently linked to a small cyclic peptide FcBP (CGGGGD-CAWHLGELVWCTGGGGC) through the hetero-bifunctional crosslinker, Mal-PEG-NHS ester. Full Abs can be tagged non-covalently to FcBP-LGA-PEI NPs with TNAs, resulting in higher affinity for specifically targeting cells and tumor tissues in vivo. It is a multifunctional and versatile nanoplatform, which can be loaded with different types of full Abs for molecular diagnosis or treatment, separately or simultaneously. Similar to gram-positive bacteria protein A/G, the 13-mer core FcBP (Fc-III, DCAWHLGELVWCT) was discovered by the bacteriophage display technique and showed a high affinity, binding to a common site between the CH2 and CH3 domains of human IgG Fc [52] . Previous studies showed that FcBP (Fc-III) is ready to covalently conjugate to the PEG linker for variable applications, such as improved technology for isolation and purification of Abs and Ab-guided NP delivery systems [85, 86] . Abs captured by FcBP fully retain their structure and function. Experimental data showed that FcBP (Fc-III) has a high affinity for human, donkey, and rabbit Abs (IgG1 and IgG2), and a weak affinity for mouse, rat, and goat Abs [85, 87] , except one study showed that FcBP (Fc-III) also binds to mouse IgG [88] . In our study, we added four extra glycine residues at each end of the 13-mer core FcBP (Fc-III) for more space and the conformational flexibility to bind to the Fc of full Abs. This strategy was successfully utilized by previously studies, in which modified FcBP was genetically incorporated into the protein-based NPs [89, 90] . In addition, we added one cysteine at both ends of the FcBP for its reaction and oriented linkage with the Mal-PEI linker without affecting functional cyclic structure of the FcBP though internal S-S bond of two cysteine residues [52] . For the functional test of our FcBP-LGA-PEI copolymer, we loaded a human anti-EGFR Ab (Cetuximab) as a model system because we demonstrated that MSLN increased EGFR expression in PC cell lines ( Figure 3A) and Cetuximab can significantly inhibit cell proliferation in a subset of PC cell lines with high expression of both MSLN and EGFR [53] . Although EGFR gene amplifications and mutations in PC are rare [91, 92] , the overexpression of EGFR is observed in 9-90% of PC tissues [93] [94] [95] and it has been associated with higher-stage and more aggressive tumors, worse clinical outcomes, poor survival, and metastasis of PC [53, 96, 97] . Thus, EGFR becomes a critical target for the treatment of PC [54, 95] . Cetuximab (Erbitux) is an anti-EGFR chimeric (mouse/human) monoclonal Ab, which was initially approved for the treatment of certain types of cancers by the FDA in 2004 [98] . Cetuximab has been conjugated to variable NPs such as PLGA [99] and gold particles [100, 101] for imaging and/or active-targeting delivery for different types of cancers. It was also covalently conjugated to low-molecular-weight branched PEI (~4−10 kDa) through a bifunctional linker PEG, and Cetuximab-functionalized PEG-PEI NP with DNA or siRNA showed its capability of binding and uptaking into the EGFR-overexpressing cells [102] . For the NP formation, we first loaded TNAs such as plasmid DNA to the FcBP-LGA-PEI copolymer, and then anti-EGFR Ab (Cetuximab) was added to the NP preparation to form the final anti-EGFR Ab/FcBP-LGA-PEI NPs, whose size was confirmed to be around 100 nm ( Figure 2C ). Usually, the size of a full IgG Ab is about 4.9 nm with the molecular weight of 150 kDa, which is much bigger than scFv (2.6 nm with 25 kDa) [35] . The optimal incorporation condition of full Ab or scFv into the LGA-PEI-based NPs should be considered differently.

The PEI-based NP delivery system has a different cellular uptake mechanism compared with the liposome-based delivery system. Liposome NPs enter cells by clathrinmediated endocytosis, whereas PEI NPs are taken up by both mechanisms of clathrinmediated endocytosis and caveolae-mediated endocytosis, which are associated with the lysosomal escape mechanism [70, 103] . Thus, PEI is more efficient for TNA delivery than liposome. Ab/cell surface receptor-medicated endocytosis could be involved in multiple mechanisms including caveolin-dependent endocytosis and clathrin-independent mechanisms such as phagocytosis and micropinocytosis. It is believed that clathrin-dependent endocytosis is the predominant mechanism for the internalization of cell-surface receptors [103, 104] . Ligand-based targeting delivery is much more efficient than non-ligandbased polymer delivery systems [105] [106] [107] . Indeed, our two active-targeting NP delivery systems with MSLN scFv or anti-EGFR Ab (Cetuximab) showed a significant enhancement of NP binding and internalization as well as gene expression in MSLN-or VFGF-expressing PC cell lines as compared with NPs without MSLN scFv or anti-EGFR Ab (Figures 3-6 ). Our LGA-PEI-based delivery systems showed consistent results when they were loaded with either miRNA mimics or GFP plasmid DNA as a model of TNAs. When a human PC cell line (Mia-MSLN) with high expression of MSLN was orthotopically injected into the pancreas of the immune-deficient mouse, the cells proliferated and formed the tumor tissues. We observed intravenous administration of MSLN scFv-LGA-PEI NPs or anti-EGFR Ab/FcBP-LGA-PEI NPs loaded with fluorescence-labelled TNAs had a significantly higher delivery efficiency into Mia-MSLN tumors than non-targeting NPs did in this cell-line-based xenograft mode in the mouse ( Figure 7C,D) .

Although the cell-line-based xenograft model is useful for the study of the molecular pathway and "the proof of concept" therapies, when used for drug discoveries, it may not reliably predict clinical efficacy [108] . This has led to the development of models by directly engrafting patient-derived tumor tissues into immunodeficient mice in order to retain the histopathologic features and molecular characteristics of the original tumor [109] . The PDX model of PC retains a greater proportion of stromal components and genetic characteristics of the human tumor specimens from which they were derived, develops regional and distant metastases, and is more predictive of patient response than the traditional cellline-based xenograft model [110, 111] . Thus, the PDX model is very useful for therapeutic efficacy, drug and biomarker discovery, and to study tumor biology and personalized medicine. For example, several recent pre-clinical studies were successfully performed to evaluate drug efficacy in subcutaneous PDX models of PC [112, 113] . For classical chemotherapeutic drugs, PC PDX models based on clinical specimens can predict 90% drug sensitivity and 97% drug resistance [114] . In the past several years, we established many PDX lines from surgical specimens of patients with PC. In the current study, we selected the PDX line (PAN3) with high expression of MSLN. We observed that NSLN scFv-LGA-PEI NPs with fluorescence-labelled miRNA mimics have a higher delivery efficiency than non-targeting NPs do in the PDX model in mice, which is more clinically relevant to the cell-line-based xenograft model.

Although polymer-based NP delivery systems for TNAs have great potential for broad clinical applications of treatment and diagnosis of many types of cancers and other diseases, many challenges and hurdles of these new technologies still exist. For examples, optimal design of the size, shape, and surface charge of NPs is difficult to define because it may be different for each individual type or subtype of cancers. In addition, tumor microenvironments such as cell density, cell type, molecular profiling, pH condition, hydrostatic pressure, and diffusion rate of NPs are critical factors, which significantly influence the delivery efficiency and therapeutic efficacy of NP medicine. Furthermore, it is difficult to study pharmacokinetics of the multi-component NP medicine in humans [115, 116] . In the current study, our LGA-PEI/NA NPs were labelled by a fluorescence dye, and used in both in vitro and in vivo experiments. For animal studies, fluorescence labelled NPs were not sensitive for the whole-body imaging. For a future study, we could load luciferase gene DNA into the LGA-PEI or Ab-linked LGA-PEI NPs, which can be used for animal experiments because chemiluminescence-based technology is more sensitive for the whole-body imaging. This method could demonstrate bio-distribution and targeted delivery of our LGA-PEI-based NP delivery systems. In the animal studies, we chose one day after NP i.v. injection for animal euthanization because this time frame was sensitive to NPs entering into cells based on our in vitro experiments. In a future study, a time cause of delivery efficiency such as 6, 12, 24, and 48 h after NP injection could generate meaningful data of delivery kinetics. Furthermore, dose dependent studies will be further studied as well.

In summary, we developed two active-targeting NP delivery technologies for TNAs from our existing novel LGA-PEI polymer. Our first technology was the covalent linkage of MSLN scFv to LGA-PEI through a bifunctional linker Mal-PEG-NHS; the MSLN scFv-LGA-PEI copolymer can efficiently load TNAs including miRNA mimics and plasmid DNA as well as mRNA to form NPs with sizes around 100 nm. Our second technology was the covalent linkage of FcBP (modified Fc-III) to LGA-PEI through Mal-PEG-NHS; the FcBP-LGA-PEI copolymer can also effectively load TNAs to form NPs and bind to Fc region of any human IgG (Abs). As a model system, we successfully linked anti-EGFR Ab (Cetuximab) to the FcBP-LGA-PEI copolymer with TNAs. We have produced high quality NPs from our polymers (LGA-PEI, MSLN scFv-LGA-PEI, anti-EGFR Ab/FcBP-LGA-PEI) with different forms of TNAs based on the analysis of the polydispersity index (PDI) of NPs [117] [118] [119] [120] . Both MSLN scFv-LGA-PEI and anti-EGFR Ab/FcBP-LGA-PEI systems are more effective and preferentially deliver TNAs into PC cells with the high expression of MSLN or EGFR, respectively, in vitro and in vivo. More importantly, we showed our new technology works in the PDX model, which is more clinically relevant than other models. Our active-targeting NP-delivery systems are a platform technology, which may have great potential for clinical applications as a new generation of delivery systems for TNAs for the treatment or molecular diagnosis of different types of cancers or other diseases.

In the future, the therapeutic efficacy of these two technologies for pancreatic cancer will be performed in clinically relevant animal models such as PDXs. We expect that these active-targeting deliveries of TNAs are more effective at inhibiting tumor growth and metastasis as well as at improving the overall survival of tumor-bearing animals as compared with passive-targeting delivery or other non-targeting delivery systems. Since our active-targeting delivery systems are the platform technology, they can be extended to other cancer types or diseases for the development of new treatment and molecular diagnosis strategies. These technologies could also be used for vaccine development. The ultimate goal of the project is to apply our technologies to broad clinical applications through extensive preclinical studies and clinical trials including efficacy, pharmacokinetics, and short-term and long-term toxicity. [70, 71] ; it was cloned into a plasmid vector and expressed in yeast (Pichia pastoris X33 strain). Synthesized 255-bases modified mRNA (single-stranded RNA) from a part of X-inactive specific transcript fragment (XIST containing 255 nucleotides) gene (mmRNA-XIST255) and control mmRNA-255 were synthesized in the RNA Core, the Houston Methodist Research Institute (Houston, TX, USA).

Synthesis of the LGA-PEI polymer was described in our previous publication [28] . The Ab fragment MSLN scFv or FcBP was conjugated to LGA-PEI through bi-functional PEG (Maleimide-PEG3500-NHS ester) ( Figure 1A and Figure S1 ). First, Mal-PEG-NHS was combined with LGA-PEI at a desired molar ratio to form maleimide-functionalized LGA-PEI (LGA-PEI-PEG-Mal). Second, MSLN scFv or FcBP was modified with SATP to convert primary amines into thiols by following the instructions provided by Thermo Fisher Scientific. Briefly, 0.4 mg MSLN scFv or FcBP was combined with 8 mg of SATP in PBS/DMSO at 25 • C for 30 min. Then, the desired product was purified using a PD-10 desalting column. The SATP groups were deacetylated using hydroxylamine and EDTA and purified with a PD-10 column. To produce MSLN scFv-LGA-PEI or FcBP-LGA-PEI, 0.2 mg of thiol-modified MSLN scFv or FcBP was combined with 50 mg of maleimidefunctionalized LGA-PEI (or at a desired molar ratio) at 25 • C for 20 h. The sulfhydryl group (-SH) of thiol-modified MSLN scFv or FcBP is added to the C=C double bond of the maleimide group in Mal-PEG-PEI-LGA to form a stable S-C bond. The amount of MSLN scFv or FcBP conjugated to LGA-PEI was quantified with the Micro BCA method (Thermo Fisher Scientific, Waltham, MA, USA) and spectrophotometry.

NPs of MSLN scFv-LGA-PEI or FcBP-LGA-PEI polymer and NAs, including plasmid DNA, mmRNA, and miRNA mimics, were prepared at different polymer to NA ratios by adding the NA solution to the water solution of polymer, and vortexing for 5 s. For example, 2 µg of plasmid DNA in 25 µL of water was added to 5 µg of the MSLN scFv-LGA-PEI or FcBP-LGA-PEI polymer in 25 µL water. These NP suspensions were kept at room temperature for 30 min before use without any further treatment. For the anti-EGFR Ab/FcBP-LGA-PEI system, we loaded the FcBP-LGA-PEI polymer with NAs to form the FcBP-LGA-PEI/NA complex; then, we added anti-EFGR Ab in the FcBP-LGA-PEI/NA complex to form the final anti-EFGR Ab/FcBP-LGA-PEI/NA NPs.

The size distributions of polymer/NA NPs were determined with dynamic light scattering using Zetasizer Nano ZS90 (Malvern Panalytical Ltd., Worcestershire, UK). The zeta potential of the NPs was measured with Zetasizer Nano ZS90 at a temperature of 25 • C. Some of the NPs were also analyzed with scanning electronic microscopy (SEM) and energy-dispersive spectroscopy (EDS).

Different types of NPs formed with our polymers and NAs were labelled with fluorescein Cy3 or DY-547 in two types of genetically engineered PC lines, Mia-PaCa 2 with stable transfection of human MSLN gene (Mia-MSLN cells) and Mia-PaCa 2 with stable transfection of empty vector cells (Mia-vector), which were previously established in our lab [32] . For cell-binding assay, Mia-vector and Mia-MSLN cells were seeded onto 8-well Chamber slides (Lab-Tek II, Thermo Fisher Scientific, Waltham, MA, USA), incubating overnight to ensure cell attachment. Fluorescein-labeled NPs were added the chamber and incubated for 2 h at 4 • C, followed by washing twice with PBS and fixation for 15 min with 4% p-formaldehyde. The cell binding efficiency of the NPs to the cells was analyzed with fluorescence images taken with an Olympus IX51 microscope and fluorescence intensity analysis with ImageJ software (NIH). For the cell internalization assay, fluorescein-labeled NPs were added to the chamber with Mia-NSLN or Mia-vector cells and incubated for 2 h at 4 • C, and then the cells were replaced with fresh culture medium and cultured at 37 • C overnight. The cell internalization efficiency of the NPs to the cells was analyzed with fluorescence images and fluorescence intensity analysis. For experiments ( Figures 5 and 6A,B) , miR-198 mimics (1 µg) labeled with a fluorescence dye Cy3 were loaded into either LGA-PEI (1.5 µg) or anti-EFGR Ab/FcBP-LGA-PEI (1.5 µg) NPs. Anti-EGFR Ab/FcBP-LGA-PEI/miR-198 mimics NPs or LGA-PEI/miR-198 mimics control NPs were added into the cell culture of Mia-MSLN cells and Mia-vector control cells at 70% confluence for the binding assay or internalization assay. LGA-PEI polymers in 12.5 µL H 2 O. NPs were kept at room temperature for 30 min. HIV gp120 Ab (0.2 µg) or anti-EGFR Ab (0.2 µg) was added to the respective NP solution and kept at room temperature for 10 min more before use. The NPs in 25 mL H 2 O diluted with 200 mL plain DMEM medium (without FBS) were then added to 10k-15k Mia-MSLN cells/well growing in 24-well plates. After 3 h, the NPs/DMEM medium was replaced with 500 mL fresh DMEM culture medium (with 15% FBS) and the cells were incubated for another 24 h before taking fluorescence images. Gene expression was measured by observing GFP-positive cells under a fluorescent microscope.

The following animal work was approved by the Office for Protection from Research Risks and Animal Welfare Act guidelines under an animal protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. For the patientderived xenograft (PDX) model, the PDX line (PAN3) was orthotopically implanted into the pancreas of an NSG mouse (NOD scid gamma mouse) for 3 weeks, when the tumor was established. Fluorescence-labeled NPs were injected to the mouse through the tail vein (4 mice/group). The mice were euthanized 1 day later, and the PAN3 tissues were harvested for immunofluorescence image and H&E staining. For the cell-line-based xenograft model, Mia-MSLN cells (5 × 10 5 in 50 µL) were orthotopically injected into the pancreas of an NSG mouse for 3 weeks, when the tumor was established. Fluorescence-labeled NPs were injected into the mouse through the tail vein (4 mice/group). The mice were euthanized the next day, and mouse tumors were harvested for fluorescence analysis. Both male and female mice (with age 8-12 weeks old and body weight 20-30 g) were used in the experiments.

All data are presented as the mean ± SEM. Nanoparticle delivery experiments in vitro were repeated five times for each group. Mouse experiments with four mice for each group were performed. Differences among three or more groups were analyzed with one-way analysis of variance (ANOVA). Student t-test was used to compare the two groups. A p value < 0.05 was regarded as significant.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/ph14090841/s1, Table S1 . Therapeutic nucleic acids approved for clinical applications; Table S2 . Mesothelin expression in different types of cancers; Figure S1 . Synthesis of FcBP-LGA-PEI polymer and nanoparticle (NP) formation with antibody (Ab) and nucleic acids; Figure S2 . Gel retardation assay to determine the nucleic acid load efficiency of our polymers (LGA-PEI, MSLN scFv-LGA-PEI and anti-EGFR Ab/FcBP-LGA-PEI); Table S3 . Nanoparticle sizes for different ratios of MSLN scFv-LGA-PEI and LGA-PEI (total 5 µg) and the same amount of the plasmid DNA (2 µg); Table S4 . Nanoparticle sizes for different ratios of MSLN scFv-LGA-PEI and LGA-PEI (total 1.5 µg) and the same amount of miR-198 mimics (1 µg); Table S5 , Nanoparticle sizes for different ratios of anti-EGFR Ab/FcBP-LGA-PEI and LGA-PEI (total 5 µg) and the same amount of plasmid DNA (2 µg); and Figure 

The authors have declared that there are no conflicts of interest.

Mortality in the United States

Transitions from heart disease to cancer as the leading cause of death in US states

Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation

Is it possible to survive pancreatic cancer?

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide

A Service of the U.S. National Institutes of Health

An RNA toolbox for cancer immunotherapy

Delivery materials for siRNA therapeutics

Non-viral vectors for gene-based therapy

Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting

Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer

Design and gene delivery activity of modified polyethylenimines

Size matters: Molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle

Ionization of poly(ethylenimine) and poly(allylamine) at various PH's

The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes

Polyethylenimine-mediated gene delivery: A mechanistic study

Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis

Degradable polyethylenimines as DNA and small interfering RNA carriers

Structural and dynamical properties of polyethylenimine in explicit water at different protonation states: A molecular dynamics study

Membrane and nuclear permeabilization by polymeric pDNA vehicles: Efficient method for gene delivery or mechanism of cytotoxicity

Recent advances in nonviral vectors for gene delivery

A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy

Poly(ethylenimine) and its role in gene delivery

Recent developments in nucleic acid delivery with polyethylenimines

Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery

New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery

Actively targeted nanocarriers for drug delivery to cancer cells

Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review

Monoclonal antibody-polyethyleneimine conjugates targeting her-2/neu or CD90 allow cell typespecific nonviral gene delivery

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Mesothelin expression correlates with prolonged patient survival in gastric cancer

Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma

Pastan, I. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

Mesothelin-targeted agents in clinical trials and in preclinical development

An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models

A novel PET imaging using 64 Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells

Mesothelin as a biomarker for targeted therapy

Value of mesothelin immunostaining in the diagnosis of mesothelioma

Application of mesothelin immunostaining in tumor diagnosis

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers

Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas

Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma

Mesothelin-targeted CARs: Driving T cells to solid tumors

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

Convergent solutions to binding at a protein-protein interface

Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib

Epidermal growth factor receptor and its role in pancreatic cancer treatment mediated by nanoparticles

Recent advances on epidermal growth factor receptor as a molecular target for breast cancer therapeutics

EGFR as a clinical marker in glioblastomas and other gliomas

Epidermal growth factor receptor ligands: Targets for optimizing treatment of metastatic colorectal cancer

A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer

inhibits the progression of renal cell carcinoma by targeting BIRC5

MiR-198 inhibits proliferation, invasion and migration of ovarian cancer cells by regulating the PI3K/Akt signaling pathway

MicroRNA-198-5p inhibits the migration and invasion of non-small lung cancer cells by targeting fucosyltransferase 8

MicroRNA-198 suppresses prostate tumorigenesis by targeting MIB1

hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations

miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1

Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin

Xist noncoding RNA could act as a tumor suppressor gene in patients with

Long non-coding RNA XIST regulates miR-106b-5p/P21 axis to suppress tumor progression in renal cell carcinoma

Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis

LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity

Ant-Mesothelin Antibodes Having High Binding Affinity

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Discovery of mesothelin and exploiting it as a target for immunotherapy

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies

Intranasal gene delivery with a polyethylenimine-PEG conjugate

Polyethyleniminegraft-poly(ethylene glycol) copolymers: Influence of copolymer block structure on DNA complexation and biological activities as gene delivery system

Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells

Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors

Thiol Michael addition reaction: A facile tool for introducing peptides into polymer-based gene delivery systems

Bio-click chemistry: Enzymatic functionalization of PEGylated capsules for targeting applications

Engineered antibody fragments and the rise of single domains

Independent versus Cooperative Binding in Polyethylenimine-DNA and Poly(L-lysine)-DNA Polyplexes

Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide

Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles

Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice

Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions

Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform

Genetically engineering encapsulin protein cage nanoparticle as a SCC-7 cell targeting optical nanoprobe

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

The epidermal growth factor receptor in human pancreatic cancer

EGFR as a potential target for the treatment of pancreatic cancer: Dilemma and controversies

Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma

A systematic analysis of FDA-approved anticancer drugs

In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles

Stability of antibody-conjugated gold nanoparticles in the endolysosomal nanoenvironment: Implications for noninvasive radiofrequencybased cancer therapy

Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide

A novel method for the assessment of targeted PEI-based nanoparticle binding based on a static surface plasmon resonance system

Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes

Clathrin-and non-clathrinmediated endocytic regulation of cell signalling

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

Clathrin-mediated endocytosis: Membrane factors pull the trigger

Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

Patientderived tumour xenografts as models for oncology drug development

An in vivo platform for translational drug development in pancreatic cancer

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors

Clonogenic assay with established human tumour xenografts: Correlation of in vitro to in vivo activity as a basis for anticancer drug discovery

Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer

Use of oppositely polarized external magnets to improve the accumulation and penetration of magnetic nanocarriers into solid tumors

Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems

Formulation and in vitro evaluation of flufenamic acid loaded deformable liposome for improved skin delivery

Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application

Optimization of mixing temperature and sonication duration in liposome preparation